{"id":143954,"date":"2025-06-01T16:21:30","date_gmt":"2025-06-01T16:21:30","guid":{"rendered":"https:\/\/teknomers.com\/en\/breast-cancer-a-simple-blood-test-to-detect-early-recurrence-teknomers\/"},"modified":"2025-06-01T16:21:32","modified_gmt":"2025-06-01T16:21:32","slug":"breast-cancer-a-simple-blood-test-to-detect-early-recurrence-teknomers","status":"publish","type":"post","link":"https:\/\/teknomers.com\/en\/breast-cancer-a-simple-blood-test-to-detect-early-recurrence-teknomers\/","title":{"rendered":"Breast cancer: A simple blood test to detect early recurrence \u2013 Teknomers."},"content":{"rendered":"\n

Revolutionizing Breast Cancer Treatment with Liquid Biopsy<\/h2>\n
\n

A groundbreaking new approach in breast cancer treatment is emerging with the potential to \u00a0detect\u00a0 biological markers of relapse through a simple blood test. This method promises to allow for early intervention and preventive treatments, representing a significant innovation in cancer care through the use of \u00a0liquid biopsy\u00a0.<\/p>\n

Liquid biopsy, or \u00a0circulating tumor DNA (ctDNA)\u00a0 analysis, tracks the progression of cancer via a \u00a0blood sample\u00a0 rather than traditional biopsies, which are more intrusive and involve extensive procedures. This technology aims to identify the presence of tumor-produced DNA in the blood, which contains vital genetic information. Such a method marks a significant \u00a0scientific advancement\u00a0 in recent years, especially in addressing the needs of women afflicted with \u00a0hormone-dependent metastatic breast cancers\u00a0, the most common type of breast tumor.<\/p>\n

At the recent 61st Congress of the \u00a0American Society of Clinical Oncology (ASCO)\u00a0 in Chicago, Professor Fran\u00e7ois-Cl\u00e9ment Bidard from the \u00a0Institut Curie\u00a0 showcased this promising technology, highlighting not only a new drug, \u00a0camizestrant (AstraZeneca)\u00a0, but also a groundbreaking approach in oncology.<\/p>\n

Typically, women suffering from \u00a0hormone-dependent\u00a0 metastatic breast cancer are treated using a combination of therapies, including \u00a0hormonal therapies\u00a0 that inhibit estrogen production and \u00a0cell proliferation inhibitors\u00a0. However, nearly 40% of these patients experience mutations in the \u00a0ESR1 gene\u00a0, which is crucial for estrogen receptor functioning. This mutation leads to \u00a0resistance\u00a0 against hormonal therapies, ultimately resulting in cancer relapse.<\/p>\n

The remarkable promise of the new blood-testing approach lies in its ability to \u00a0detect mutations\u00a0 months before they lead to cancer progression. Early identification allows for timely \u00a0modifications\u00a0 in hormonal therapy, potentially complemented by cell cycle inhibitors, all aimed at minimizing the risk of tumor \u00a0recurrence\u00a0.<\/p>\n

This concept was first supported by a French academic trial called \u00a0Pada-1\u00a0, directed by Professor Bidard, demonstrating its potential efficacy. It is now further substantiated by the results from the international Phase III clinical trial, \u00a0Serena-6\u00a0, evaluating camizestrant.<\/p>\n

The study monitored almost 3,000 patients, conducting blood tests every 2 to 3 months. Out of these, \u00a0315 patients developed a mutation\u00a0 without any current cancer progression. They were divided into two groups: a control group that continued the standard treatment and an experimental group that received camizestrant along with the cell cycle inhibitor. The results were astounding.<\/p>\n

Patients on the new oral treatment witnessed a \u00a056% reduction\u00a0 in their risk of cancer progression, effectively delaying recurrence by about six months on average. After 12 months, the progression-free survival rate was \u00a060.7%\u00a0 for those on camizestrant compared to just \u00a033.4%\u00a0 for the control group. At the two-year mark, progression-free survival soared to \u00a029.7%\u00a0 versus \u00a05.4%\u00a0, marking this as a \u00a0revolutionary approach\u00a0 in breast cancer treatment.<\/p>\n

Professor Bidard emphasized that this method represents a primary milestone in the field of breast cancer treatment, potentially paving the way for broader applications in oncology beyond breast cancer.<\/p>\n

For over a decade, research on \u00a0circulating tumor DNA\u00a0 has flourished, fueled by advances in molecular biology, giving rise to thousands of scientific studies and increasingly high hopes for practical applications in oncology. The implications extend toward a vision for a more \u00a0personalized and preventive\u00a0 approach to cancer treatment that is also less invasive for patients.<\/p>\n

This recent breakthrough indicates that the \u00a0pharmaceutical industry\u00a0 is beginning to realize the potential of liquid biopsy. This realization stands out as a notable step toward obtaining regulatory approvals for new therapeutic molecules based on liquid biopsy findings. As noted by Professor Bidard, this may open the door for other companies to explore this innovative approach to initiating cancer treatments.<\/p>\n

With the growing incidence of hormone-dependent breast cancer globally, competition among pharmaceutical labs is intensifying as they seek to develop next-generation hormonal therapies that can yield substantial \u00a0profits\u00a0. AstraZeneca is positioning camizestrant as a \u00a0first-line medication\u00a0, striving to distinguish itself amidst competitors such as Roche, Pfizer, and Eli Lilly, who are also exploring various approaches within this therapeutic domain.<\/p>\n<\/div>\n

In conclusion, the advent of liquid biopsy technology heralds a new chapter in breast cancer treatment, offering hope for timely and less invasive interventions tailored to individual patient needs. As research progresses and more therapies become available, patients may look forward to a future where cancer management is not only more effective but also more humane.<\/p>\n


\n
General News – 2<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"

Revolutionizing Breast Cancer Treatment with Liquid Biopsy A groundbreaking new approach in breast cancer treatment is emerging with the potential to \u00a0detect\u00a0 biological markers of relapse through a simple blood test. This method promises to allow for early intervention and preventive treatments, representing a significant innovation in cancer care through the use of \u00a0liquid biopsy\u00a0. […]<\/p>\n","protected":false},"author":1,"featured_media":143955,"comment_status":"closed","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[36400],"tags":[],"class_list":["post-143954","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-health"],"_links":{"self":[{"href":"https:\/\/teknomers.com\/en\/wp-json\/wp\/v2\/posts\/143954","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/teknomers.com\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/teknomers.com\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/teknomers.com\/en\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/teknomers.com\/en\/wp-json\/wp\/v2\/comments?post=143954"}],"version-history":[{"count":0,"href":"https:\/\/teknomers.com\/en\/wp-json\/wp\/v2\/posts\/143954\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/teknomers.com\/en\/wp-json\/wp\/v2\/media\/143955"}],"wp:attachment":[{"href":"https:\/\/teknomers.com\/en\/wp-json\/wp\/v2\/media?parent=143954"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/teknomers.com\/en\/wp-json\/wp\/v2\/categories?post=143954"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/teknomers.com\/en\/wp-json\/wp\/v2\/tags?post=143954"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}